nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—migraine—Prednisone—prostate cancer	0.583	1	CpDpCtD
Rizatriptan—CYP1A2—Flutamide—prostate cancer	0.0387	0.347	CbGbCtD
Rizatriptan—CYP1A2—Estrone—prostate cancer	0.028	0.251	CbGbCtD
Rizatriptan—CYP1A2—Conjugated Estrogens—prostate cancer	0.0183	0.164	CbGbCtD
Rizatriptan—CYP1A2—Estradiol—prostate cancer	0.0161	0.144	CbGbCtD
Rizatriptan—CYP1A2—Etoposide—prostate cancer	0.0105	0.0941	CbGbCtD
Rizatriptan—Melatonin—CALR—prostate cancer	0.00202	0.413	CrCbGaD
Rizatriptan—Melatonin—CYP1B1—prostate cancer	0.00044	0.0901	CrCbGaD
Rizatriptan—Melatonin—MPO—prostate cancer	0.000396	0.0811	CrCbGaD
Rizatriptan—Almotriptan—CYP2E1—prostate cancer	0.000357	0.073	CrCbGaD
Rizatriptan—Almotriptan—CYP2C19—prostate cancer	0.000353	0.0723	CrCbGaD
Rizatriptan—Melatonin—CYP19A1—prostate cancer	0.000323	0.0661	CrCbGaD
Rizatriptan—Melatonin—ESR1—prostate cancer	0.000297	0.0609	CrCbGaD
Rizatriptan—Melatonin—CYP2C19—prostate cancer	0.000239	0.0488	CrCbGaD
Rizatriptan—Melatonin—CYP1A1—prostate cancer	0.000238	0.0487	CrCbGaD
Rizatriptan—Almotriptan—CYP3A4—prostate cancer	0.000225	0.046	CrCbGaD
Rizatriptan—Dermatitis—Estradiol—prostate cancer	6.45e-05	0.000311	CcSEcCtD
Rizatriptan—Confusional state—Capecitabine—prostate cancer	6.44e-05	0.00031	CcSEcCtD
Rizatriptan—Tachycardia—Docetaxel—prostate cancer	6.44e-05	0.00031	CcSEcCtD
Rizatriptan—Headache—Estradiol—prostate cancer	6.41e-05	0.000309	CcSEcCtD
Rizatriptan—Agitation—Prednisone—prostate cancer	6.4e-05	0.000308	CcSEcCtD
Rizatriptan—Oedema—Capecitabine—prostate cancer	6.39e-05	0.000307	CcSEcCtD
Rizatriptan—Bradycardia—Epirubicin—prostate cancer	6.37e-05	0.000307	CcSEcCtD
Rizatriptan—Angioedema—Prednisone—prostate cancer	6.37e-05	0.000307	CcSEcCtD
Rizatriptan—Urticaria—Etoposide—prostate cancer	6.3e-05	0.000304	CcSEcCtD
Rizatriptan—Anorexia—Docetaxel—prostate cancer	6.29e-05	0.000303	CcSEcCtD
Rizatriptan—Shock—Capecitabine—prostate cancer	6.28e-05	0.000303	CcSEcCtD
Rizatriptan—Abdominal pain—Etoposide—prostate cancer	6.27e-05	0.000302	CcSEcCtD
Rizatriptan—Body temperature increased—Etoposide—prostate cancer	6.27e-05	0.000302	CcSEcCtD
Rizatriptan—Nervous system disorder—Capecitabine—prostate cancer	6.26e-05	0.000302	CcSEcCtD
Rizatriptan—Vertigo—Prednisone—prostate cancer	6.26e-05	0.000302	CcSEcCtD
Rizatriptan—Syncope—Prednisone—prostate cancer	6.25e-05	0.000301	CcSEcCtD
Rizatriptan—Tachycardia—Capecitabine—prostate cancer	6.23e-05	0.0003	CcSEcCtD
Rizatriptan—Hypoaesthesia—Epirubicin—prostate cancer	6.23e-05	0.0003	CcSEcCtD
Rizatriptan—Pharyngitis—Epirubicin—prostate cancer	6.21e-05	0.000299	CcSEcCtD
Rizatriptan—Sweating—Doxorubicin—prostate cancer	6.19e-05	0.000298	CcSEcCtD
Rizatriptan—Hyperhidrosis—Capecitabine—prostate cancer	6.17e-05	0.000297	CcSEcCtD
Rizatriptan—Loss of consciousness—Prednisone—prostate cancer	6.13e-05	0.000295	CcSEcCtD
Rizatriptan—Epistaxis—Doxorubicin—prostate cancer	6.09e-05	0.000293	CcSEcCtD
Rizatriptan—Anorexia—Capecitabine—prostate cancer	6.09e-05	0.000293	CcSEcCtD
Rizatriptan—Nausea—Estradiol—prostate cancer	6.08e-05	0.000293	CcSEcCtD
Rizatriptan—Vomiting—Mitoxantrone—prostate cancer	6.07e-05	0.000292	CcSEcCtD
Rizatriptan—Convulsion—Prednisone—prostate cancer	6.04e-05	0.000291	CcSEcCtD
Rizatriptan—Hypertension—Prednisone—prostate cancer	6.02e-05	0.00029	CcSEcCtD
Rizatriptan—Rash—Mitoxantrone—prostate cancer	6.02e-05	0.00029	CcSEcCtD
Rizatriptan—Dermatitis—Mitoxantrone—prostate cancer	6.01e-05	0.000289	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.01e-05	0.000289	CcSEcCtD
Rizatriptan—Headache—Mitoxantrone—prostate cancer	5.98e-05	0.000288	CcSEcCtD
Rizatriptan—Insomnia—Docetaxel—prostate cancer	5.96e-05	0.000287	CcSEcCtD
Rizatriptan—Arthralgia—Prednisone—prostate cancer	5.93e-05	0.000286	CcSEcCtD
Rizatriptan—Myalgia—Prednisone—prostate cancer	5.93e-05	0.000286	CcSEcCtD
Rizatriptan—Paraesthesia—Docetaxel—prostate cancer	5.92e-05	0.000285	CcSEcCtD
Rizatriptan—Anxiety—Prednisone—prostate cancer	5.91e-05	0.000285	CcSEcCtD
Rizatriptan—Bradycardia—Doxorubicin—prostate cancer	5.9e-05	0.000284	CcSEcCtD
Rizatriptan—Dyspnoea—Docetaxel—prostate cancer	5.88e-05	0.000283	CcSEcCtD
Rizatriptan—Somnolence—Docetaxel—prostate cancer	5.86e-05	0.000282	CcSEcCtD
Rizatriptan—Discomfort—Prednisone—prostate cancer	5.86e-05	0.000282	CcSEcCtD
Rizatriptan—Hypersensitivity—Etoposide—prostate cancer	5.85e-05	0.000282	CcSEcCtD
Rizatriptan—Tinnitus—Epirubicin—prostate cancer	5.84e-05	0.000281	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.82e-05	0.00028	CcSEcCtD
Rizatriptan—Flushing—Epirubicin—prostate cancer	5.81e-05	0.00028	CcSEcCtD
Rizatriptan—Dyspepsia—Docetaxel—prostate cancer	5.81e-05	0.00028	CcSEcCtD
Rizatriptan—Insomnia—Capecitabine—prostate cancer	5.78e-05	0.000278	CcSEcCtD
Rizatriptan—Hypoaesthesia—Doxorubicin—prostate cancer	5.76e-05	0.000278	CcSEcCtD
Rizatriptan—Pharyngitis—Doxorubicin—prostate cancer	5.75e-05	0.000277	CcSEcCtD
Rizatriptan—Paraesthesia—Capecitabine—prostate cancer	5.73e-05	0.000276	CcSEcCtD
Rizatriptan—Decreased appetite—Docetaxel—prostate cancer	5.73e-05	0.000276	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Docetaxel—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Asthenia—Etoposide—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Dyspnoea—Capecitabine—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Oedema—Prednisone—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Anaphylactic shock—Prednisone—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Fatigue—Docetaxel—prostate cancer	5.69e-05	0.000274	CcSEcCtD
Rizatriptan—Angiopathy—Epirubicin—prostate cancer	5.68e-05	0.000274	CcSEcCtD
Rizatriptan—Nausea—Mitoxantrone—prostate cancer	5.67e-05	0.000273	CcSEcCtD
Rizatriptan—Constipation—Docetaxel—prostate cancer	5.64e-05	0.000272	CcSEcCtD
Rizatriptan—Pain—Docetaxel—prostate cancer	5.64e-05	0.000272	CcSEcCtD
Rizatriptan—Dyspepsia—Capecitabine—prostate cancer	5.62e-05	0.000271	CcSEcCtD
Rizatriptan—Chills—Epirubicin—prostate cancer	5.62e-05	0.000271	CcSEcCtD
Rizatriptan—Pruritus—Etoposide—prostate cancer	5.61e-05	0.00027	CcSEcCtD
Rizatriptan—Shock—Prednisone—prostate cancer	5.6e-05	0.000269	CcSEcCtD
Rizatriptan—Arrhythmia—Epirubicin—prostate cancer	5.59e-05	0.000269	CcSEcCtD
Rizatriptan—Nervous system disorder—Prednisone—prostate cancer	5.58e-05	0.000269	CcSEcCtD
Rizatriptan—Tachycardia—Prednisone—prostate cancer	5.55e-05	0.000267	CcSEcCtD
Rizatriptan—Decreased appetite—Capecitabine—prostate cancer	5.55e-05	0.000267	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Capecitabine—prostate cancer	5.51e-05	0.000265	CcSEcCtD
Rizatriptan—Fatigue—Capecitabine—prostate cancer	5.51e-05	0.000265	CcSEcCtD
Rizatriptan—Hyperhidrosis—Prednisone—prostate cancer	5.5e-05	0.000265	CcSEcCtD
Rizatriptan—Mental disorder—Epirubicin—prostate cancer	5.49e-05	0.000264	CcSEcCtD
Rizatriptan—Pain—Capecitabine—prostate cancer	5.46e-05	0.000263	CcSEcCtD
Rizatriptan—Constipation—Capecitabine—prostate cancer	5.46e-05	0.000263	CcSEcCtD
Rizatriptan—Erythema—Epirubicin—prostate cancer	5.45e-05	0.000262	CcSEcCtD
Rizatriptan—Feeling abnormal—Docetaxel—prostate cancer	5.43e-05	0.000262	CcSEcCtD
Rizatriptan—Diarrhoea—Etoposide—prostate cancer	5.43e-05	0.000261	CcSEcCtD
Rizatriptan—Anorexia—Prednisone—prostate cancer	5.42e-05	0.000261	CcSEcCtD
Rizatriptan—Tinnitus—Doxorubicin—prostate cancer	5.4e-05	0.00026	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Docetaxel—prostate cancer	5.39e-05	0.00026	CcSEcCtD
Rizatriptan—Flushing—Doxorubicin—prostate cancer	5.38e-05	0.000259	CcSEcCtD
Rizatriptan—Flatulence—Epirubicin—prostate cancer	5.37e-05	0.000259	CcSEcCtD
Rizatriptan—Tension—Epirubicin—prostate cancer	5.35e-05	0.000258	CcSEcCtD
Rizatriptan—Dysgeusia—Epirubicin—prostate cancer	5.34e-05	0.000257	CcSEcCtD
Rizatriptan—Nervousness—Epirubicin—prostate cancer	5.29e-05	0.000255	CcSEcCtD
Rizatriptan—Feeling abnormal—Capecitabine—prostate cancer	5.26e-05	0.000253	CcSEcCtD
Rizatriptan—Angiopathy—Doxorubicin—prostate cancer	5.26e-05	0.000253	CcSEcCtD
Rizatriptan—Dizziness—Etoposide—prostate cancer	5.25e-05	0.000253	CcSEcCtD
Rizatriptan—Muscle spasms—Epirubicin—prostate cancer	5.24e-05	0.000252	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Capecitabine—prostate cancer	5.22e-05	0.000251	CcSEcCtD
Rizatriptan—Abdominal pain—Docetaxel—prostate cancer	5.21e-05	0.000251	CcSEcCtD
Rizatriptan—Body temperature increased—Docetaxel—prostate cancer	5.21e-05	0.000251	CcSEcCtD
Rizatriptan—Chills—Doxorubicin—prostate cancer	5.2e-05	0.00025	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Prednisone—prostate cancer	5.18e-05	0.00025	CcSEcCtD
Rizatriptan—Arrhythmia—Doxorubicin—prostate cancer	5.18e-05	0.000249	CcSEcCtD
Rizatriptan—Insomnia—Prednisone—prostate cancer	5.14e-05	0.000248	CcSEcCtD
Rizatriptan—Vision blurred—Epirubicin—prostate cancer	5.14e-05	0.000247	CcSEcCtD
Rizatriptan—Paraesthesia—Prednisone—prostate cancer	5.11e-05	0.000246	CcSEcCtD
Rizatriptan—Mental disorder—Doxorubicin—prostate cancer	5.08e-05	0.000244	CcSEcCtD
Rizatriptan—Urticaria—Capecitabine—prostate cancer	5.07e-05	0.000244	CcSEcCtD
Rizatriptan—Abdominal pain—Capecitabine—prostate cancer	5.05e-05	0.000243	CcSEcCtD
Rizatriptan—Body temperature increased—Capecitabine—prostate cancer	5.05e-05	0.000243	CcSEcCtD
Rizatriptan—Vomiting—Etoposide—prostate cancer	5.05e-05	0.000243	CcSEcCtD
Rizatriptan—Erythema—Doxorubicin—prostate cancer	5.04e-05	0.000243	CcSEcCtD
Rizatriptan—Agitation—Epirubicin—prostate cancer	5.01e-05	0.000241	CcSEcCtD
Rizatriptan—Dyspepsia—Prednisone—prostate cancer	5.01e-05	0.000241	CcSEcCtD
Rizatriptan—Rash—Etoposide—prostate cancer	5e-05	0.000241	CcSEcCtD
Rizatriptan—Dermatitis—Etoposide—prostate cancer	5e-05	0.000241	CcSEcCtD
Rizatriptan—Headache—Etoposide—prostate cancer	4.97e-05	0.000239	CcSEcCtD
Rizatriptan—Flatulence—Doxorubicin—prostate cancer	4.97e-05	0.000239	CcSEcCtD
Rizatriptan—Tension—Doxorubicin—prostate cancer	4.95e-05	0.000238	CcSEcCtD
Rizatriptan—Decreased appetite—Prednisone—prostate cancer	4.94e-05	0.000238	CcSEcCtD
Rizatriptan—Dysgeusia—Doxorubicin—prostate cancer	4.94e-05	0.000238	CcSEcCtD
Rizatriptan—Fatigue—Prednisone—prostate cancer	4.9e-05	0.000236	CcSEcCtD
Rizatriptan—Nervousness—Doxorubicin—prostate cancer	4.9e-05	0.000236	CcSEcCtD
Rizatriptan—Vertigo—Epirubicin—prostate cancer	4.9e-05	0.000236	CcSEcCtD
Rizatriptan—Syncope—Epirubicin—prostate cancer	4.89e-05	0.000235	CcSEcCtD
Rizatriptan—Constipation—Prednisone—prostate cancer	4.86e-05	0.000234	CcSEcCtD
Rizatriptan—Hypersensitivity—Docetaxel—prostate cancer	4.86e-05	0.000234	CcSEcCtD
Rizatriptan—Muscle spasms—Doxorubicin—prostate cancer	4.85e-05	0.000233	CcSEcCtD
Rizatriptan—Palpitations—Epirubicin—prostate cancer	4.82e-05	0.000232	CcSEcCtD
Rizatriptan—Loss of consciousness—Epirubicin—prostate cancer	4.79e-05	0.000231	CcSEcCtD
Rizatriptan—Cough—Epirubicin—prostate cancer	4.76e-05	0.000229	CcSEcCtD
Rizatriptan—Vision blurred—Doxorubicin—prostate cancer	4.75e-05	0.000229	CcSEcCtD
Rizatriptan—Asthenia—Docetaxel—prostate cancer	4.73e-05	0.000228	CcSEcCtD
Rizatriptan—Convulsion—Epirubicin—prostate cancer	4.72e-05	0.000227	CcSEcCtD
Rizatriptan—Nausea—Etoposide—prostate cancer	4.71e-05	0.000227	CcSEcCtD
Rizatriptan—Hypertension—Epirubicin—prostate cancer	4.71e-05	0.000227	CcSEcCtD
Rizatriptan—Hypersensitivity—Capecitabine—prostate cancer	4.7e-05	0.000227	CcSEcCtD
Rizatriptan—Feeling abnormal—Prednisone—prostate cancer	4.69e-05	0.000226	CcSEcCtD
Rizatriptan—Pruritus—Docetaxel—prostate cancer	4.67e-05	0.000225	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Prednisone—prostate cancer	4.65e-05	0.000224	CcSEcCtD
Rizatriptan—Chest pain—Epirubicin—prostate cancer	4.64e-05	0.000223	CcSEcCtD
Rizatriptan—Arthralgia—Epirubicin—prostate cancer	4.64e-05	0.000223	CcSEcCtD
Rizatriptan—Myalgia—Epirubicin—prostate cancer	4.64e-05	0.000223	CcSEcCtD
Rizatriptan—Agitation—Doxorubicin—prostate cancer	4.63e-05	0.000223	CcSEcCtD
Rizatriptan—Anxiety—Epirubicin—prostate cancer	4.62e-05	0.000223	CcSEcCtD
Rizatriptan—Discomfort—Epirubicin—prostate cancer	4.58e-05	0.000221	CcSEcCtD
Rizatriptan—Asthenia—Capecitabine—prostate cancer	4.58e-05	0.000221	CcSEcCtD
Rizatriptan—Dry mouth—Epirubicin—prostate cancer	4.54e-05	0.000219	CcSEcCtD
Rizatriptan—Vertigo—Doxorubicin—prostate cancer	4.53e-05	0.000218	CcSEcCtD
Rizatriptan—Syncope—Doxorubicin—prostate cancer	4.52e-05	0.000218	CcSEcCtD
Rizatriptan—Urticaria—Prednisone—prostate cancer	4.52e-05	0.000218	CcSEcCtD
Rizatriptan—Pruritus—Capecitabine—prostate cancer	4.52e-05	0.000218	CcSEcCtD
Rizatriptan—Diarrhoea—Docetaxel—prostate cancer	4.51e-05	0.000217	CcSEcCtD
Rizatriptan—Abdominal pain—Prednisone—prostate cancer	4.5e-05	0.000217	CcSEcCtD
Rizatriptan—Body temperature increased—Prednisone—prostate cancer	4.5e-05	0.000217	CcSEcCtD
Rizatriptan—Confusional state—Epirubicin—prostate cancer	4.49e-05	0.000216	CcSEcCtD
Rizatriptan—Palpitations—Doxorubicin—prostate cancer	4.46e-05	0.000215	CcSEcCtD
Rizatriptan—Oedema—Epirubicin—prostate cancer	4.45e-05	0.000214	CcSEcCtD
Rizatriptan—Anaphylactic shock—Epirubicin—prostate cancer	4.45e-05	0.000214	CcSEcCtD
Rizatriptan—Loss of consciousness—Doxorubicin—prostate cancer	4.43e-05	0.000213	CcSEcCtD
Rizatriptan—Cough—Doxorubicin—prostate cancer	4.4e-05	0.000212	CcSEcCtD
Rizatriptan—Shock—Epirubicin—prostate cancer	4.38e-05	0.000211	CcSEcCtD
Rizatriptan—Convulsion—Doxorubicin—prostate cancer	4.37e-05	0.00021	CcSEcCtD
Rizatriptan—Diarrhoea—Capecitabine—prostate cancer	4.37e-05	0.00021	CcSEcCtD
Rizatriptan—Nervous system disorder—Epirubicin—prostate cancer	4.36e-05	0.00021	CcSEcCtD
Rizatriptan—Dizziness—Docetaxel—prostate cancer	4.36e-05	0.00021	CcSEcCtD
Rizatriptan—Hypertension—Doxorubicin—prostate cancer	4.35e-05	0.00021	CcSEcCtD
Rizatriptan—Tachycardia—Epirubicin—prostate cancer	4.34e-05	0.000209	CcSEcCtD
Rizatriptan—Hyperhidrosis—Epirubicin—prostate cancer	4.3e-05	0.000207	CcSEcCtD
Rizatriptan—Arthralgia—Doxorubicin—prostate cancer	4.29e-05	0.000207	CcSEcCtD
Rizatriptan—Chest pain—Doxorubicin—prostate cancer	4.29e-05	0.000207	CcSEcCtD
Rizatriptan—Myalgia—Doxorubicin—prostate cancer	4.29e-05	0.000207	CcSEcCtD
Rizatriptan—Anxiety—Doxorubicin—prostate cancer	4.28e-05	0.000206	CcSEcCtD
Rizatriptan—Discomfort—Doxorubicin—prostate cancer	4.24e-05	0.000204	CcSEcCtD
Rizatriptan—Anorexia—Epirubicin—prostate cancer	4.24e-05	0.000204	CcSEcCtD
Rizatriptan—Dizziness—Capecitabine—prostate cancer	4.22e-05	0.000203	CcSEcCtD
Rizatriptan—Dry mouth—Doxorubicin—prostate cancer	4.2e-05	0.000202	CcSEcCtD
Rizatriptan—Vomiting—Docetaxel—prostate cancer	4.19e-05	0.000202	CcSEcCtD
Rizatriptan—Hypersensitivity—Prednisone—prostate cancer	4.19e-05	0.000202	CcSEcCtD
Rizatriptan—Rash—Docetaxel—prostate cancer	4.16e-05	0.0002	CcSEcCtD
Rizatriptan—Dermatitis—Docetaxel—prostate cancer	4.15e-05	0.0002	CcSEcCtD
Rizatriptan—Confusional state—Doxorubicin—prostate cancer	4.15e-05	0.0002	CcSEcCtD
Rizatriptan—Headache—Docetaxel—prostate cancer	4.13e-05	0.000199	CcSEcCtD
Rizatriptan—Anaphylactic shock—Doxorubicin—prostate cancer	4.12e-05	0.000198	CcSEcCtD
Rizatriptan—Oedema—Doxorubicin—prostate cancer	4.12e-05	0.000198	CcSEcCtD
Rizatriptan—Asthenia—Prednisone—prostate cancer	4.08e-05	0.000197	CcSEcCtD
Rizatriptan—Vomiting—Capecitabine—prostate cancer	4.06e-05	0.000196	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.05e-05	0.000195	CcSEcCtD
Rizatriptan—Shock—Doxorubicin—prostate cancer	4.05e-05	0.000195	CcSEcCtD
Rizatriptan—Nervous system disorder—Doxorubicin—prostate cancer	4.04e-05	0.000194	CcSEcCtD
Rizatriptan—Rash—Capecitabine—prostate cancer	4.03e-05	0.000194	CcSEcCtD
Rizatriptan—Pruritus—Prednisone—prostate cancer	4.02e-05	0.000194	CcSEcCtD
Rizatriptan—Insomnia—Epirubicin—prostate cancer	4.02e-05	0.000194	CcSEcCtD
Rizatriptan—Dermatitis—Capecitabine—prostate cancer	4.02e-05	0.000194	CcSEcCtD
Rizatriptan—Tachycardia—Doxorubicin—prostate cancer	4.02e-05	0.000193	CcSEcCtD
Rizatriptan—Headache—Capecitabine—prostate cancer	4e-05	0.000193	CcSEcCtD
Rizatriptan—Paraesthesia—Epirubicin—prostate cancer	3.99e-05	0.000192	CcSEcCtD
Rizatriptan—Hyperhidrosis—Doxorubicin—prostate cancer	3.98e-05	0.000192	CcSEcCtD
Rizatriptan—Dyspnoea—Epirubicin—prostate cancer	3.97e-05	0.000191	CcSEcCtD
Rizatriptan—Somnolence—Epirubicin—prostate cancer	3.95e-05	0.00019	CcSEcCtD
Rizatriptan—Anorexia—Doxorubicin—prostate cancer	3.92e-05	0.000189	CcSEcCtD
Rizatriptan—Nausea—Docetaxel—prostate cancer	3.92e-05	0.000189	CcSEcCtD
Rizatriptan—Dyspepsia—Epirubicin—prostate cancer	3.92e-05	0.000189	CcSEcCtD
Rizatriptan—Diarrhoea—Prednisone—prostate cancer	3.89e-05	0.000187	CcSEcCtD
Rizatriptan—Decreased appetite—Epirubicin—prostate cancer	3.87e-05	0.000186	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Epirubicin—prostate cancer	3.84e-05	0.000185	CcSEcCtD
Rizatriptan—Fatigue—Epirubicin—prostate cancer	3.84e-05	0.000185	CcSEcCtD
Rizatriptan—Pain—Epirubicin—prostate cancer	3.8e-05	0.000183	CcSEcCtD
Rizatriptan—Constipation—Epirubicin—prostate cancer	3.8e-05	0.000183	CcSEcCtD
Rizatriptan—Nausea—Capecitabine—prostate cancer	3.79e-05	0.000183	CcSEcCtD
Rizatriptan—Dizziness—Prednisone—prostate cancer	3.76e-05	0.000181	CcSEcCtD
Rizatriptan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.75e-05	0.000181	CcSEcCtD
Rizatriptan—Insomnia—Doxorubicin—prostate cancer	3.72e-05	0.000179	CcSEcCtD
Rizatriptan—Paraesthesia—Doxorubicin—prostate cancer	3.7e-05	0.000178	CcSEcCtD
Rizatriptan—Dyspnoea—Doxorubicin—prostate cancer	3.67e-05	0.000177	CcSEcCtD
Rizatriptan—Feeling abnormal—Epirubicin—prostate cancer	3.67e-05	0.000177	CcSEcCtD
Rizatriptan—Somnolence—Doxorubicin—prostate cancer	3.66e-05	0.000176	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Epirubicin—prostate cancer	3.64e-05	0.000175	CcSEcCtD
Rizatriptan—Dyspepsia—Doxorubicin—prostate cancer	3.62e-05	0.000174	CcSEcCtD
Rizatriptan—Vomiting—Prednisone—prostate cancer	3.62e-05	0.000174	CcSEcCtD
Rizatriptan—Rash—Prednisone—prostate cancer	3.59e-05	0.000173	CcSEcCtD
Rizatriptan—Dermatitis—Prednisone—prostate cancer	3.58e-05	0.000173	CcSEcCtD
Rizatriptan—Decreased appetite—Doxorubicin—prostate cancer	3.58e-05	0.000172	CcSEcCtD
Rizatriptan—Headache—Prednisone—prostate cancer	3.56e-05	0.000172	CcSEcCtD
Rizatriptan—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.55e-05	0.000171	CcSEcCtD
Rizatriptan—Fatigue—Doxorubicin—prostate cancer	3.55e-05	0.000171	CcSEcCtD
Rizatriptan—Urticaria—Epirubicin—prostate cancer	3.53e-05	0.00017	CcSEcCtD
Rizatriptan—Constipation—Doxorubicin—prostate cancer	3.52e-05	0.000169	CcSEcCtD
Rizatriptan—Pain—Doxorubicin—prostate cancer	3.52e-05	0.000169	CcSEcCtD
Rizatriptan—Abdominal pain—Epirubicin—prostate cancer	3.52e-05	0.000169	CcSEcCtD
Rizatriptan—Body temperature increased—Epirubicin—prostate cancer	3.52e-05	0.000169	CcSEcCtD
Rizatriptan—Feeling abnormal—Doxorubicin—prostate cancer	3.39e-05	0.000163	CcSEcCtD
Rizatriptan—Nausea—Prednisone—prostate cancer	3.38e-05	0.000163	CcSEcCtD
Rizatriptan—Gastrointestinal pain—Doxorubicin—prostate cancer	3.37e-05	0.000162	CcSEcCtD
Rizatriptan—Hypersensitivity—Epirubicin—prostate cancer	3.28e-05	0.000158	CcSEcCtD
Rizatriptan—Urticaria—Doxorubicin—prostate cancer	3.27e-05	0.000157	CcSEcCtD
Rizatriptan—Abdominal pain—Doxorubicin—prostate cancer	3.25e-05	0.000157	CcSEcCtD
Rizatriptan—Body temperature increased—Doxorubicin—prostate cancer	3.25e-05	0.000157	CcSEcCtD
Rizatriptan—Asthenia—Epirubicin—prostate cancer	3.19e-05	0.000154	CcSEcCtD
Rizatriptan—Pruritus—Epirubicin—prostate cancer	3.15e-05	0.000152	CcSEcCtD
Rizatriptan—Diarrhoea—Epirubicin—prostate cancer	3.04e-05	0.000147	CcSEcCtD
Rizatriptan—Hypersensitivity—Doxorubicin—prostate cancer	3.03e-05	0.000146	CcSEcCtD
Rizatriptan—Asthenia—Doxorubicin—prostate cancer	2.95e-05	0.000142	CcSEcCtD
Rizatriptan—Dizziness—Epirubicin—prostate cancer	2.94e-05	0.000142	CcSEcCtD
Rizatriptan—Pruritus—Doxorubicin—prostate cancer	2.91e-05	0.00014	CcSEcCtD
Rizatriptan—Vomiting—Epirubicin—prostate cancer	2.83e-05	0.000136	CcSEcCtD
Rizatriptan—Diarrhoea—Doxorubicin—prostate cancer	2.82e-05	0.000136	CcSEcCtD
Rizatriptan—Rash—Epirubicin—prostate cancer	2.8e-05	0.000135	CcSEcCtD
Rizatriptan—Dermatitis—Epirubicin—prostate cancer	2.8e-05	0.000135	CcSEcCtD
Rizatriptan—Headache—Epirubicin—prostate cancer	2.79e-05	0.000134	CcSEcCtD
Rizatriptan—Dizziness—Doxorubicin—prostate cancer	2.72e-05	0.000131	CcSEcCtD
Rizatriptan—Nausea—Epirubicin—prostate cancer	2.64e-05	0.000127	CcSEcCtD
Rizatriptan—Vomiting—Doxorubicin—prostate cancer	2.62e-05	0.000126	CcSEcCtD
Rizatriptan—Rash—Doxorubicin—prostate cancer	2.6e-05	0.000125	CcSEcCtD
Rizatriptan—Dermatitis—Doxorubicin—prostate cancer	2.59e-05	0.000125	CcSEcCtD
Rizatriptan—Headache—Doxorubicin—prostate cancer	2.58e-05	0.000124	CcSEcCtD
Rizatriptan—Nausea—Doxorubicin—prostate cancer	2.44e-05	0.000118	CcSEcCtD
Rizatriptan—HTR1B—Signaling Pathways—KDR—prostate cancer	7.79e-06	8.39e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CTNNB1—prostate cancer	7.79e-06	8.38e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ESR1—prostate cancer	7.75e-06	8.35e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTO1—prostate cancer	7.73e-06	8.33e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HSD3B2—prostate cancer	7.73e-06	8.33e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NAT2—prostate cancer	7.73e-06	8.33e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CG—prostate cancer	7.69e-06	8.28e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MMP9—prostate cancer	7.63e-06	8.22e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—CDKN1A—prostate cancer	7.61e-06	8.19e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ESR1—prostate cancer	7.59e-06	8.17e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PTEN—prostate cancer	7.59e-06	8.17e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—BAD—prostate cancer	7.57e-06	8.15e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IGF1R—prostate cancer	7.54e-06	8.12e-05	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—CXCL8—prostate cancer	7.5e-06	8.08e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—JAK2—prostate cancer	7.47e-06	8.04e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	7.44e-06	8.01e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PLCB2—prostate cancer	7.42e-06	7.98e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—LRP2—prostate cancer	7.42e-06	7.98e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2C18—prostate cancer	7.42e-06	7.98e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—BAD—prostate cancer	7.41e-06	7.98e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—AKT1—prostate cancer	7.4e-06	7.97e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—APC—prostate cancer	7.33e-06	7.89e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CG—prostate cancer	7.33e-06	7.89e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—INS—prostate cancer	7.28e-06	7.84e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—P4HB—prostate cancer	7.27e-06	7.83e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IRS1—prostate cancer	7.24e-06	7.8e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EGF—prostate cancer	7.24e-06	7.8e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EP300—prostate cancer	7.24e-06	7.79e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—LPL—prostate cancer	7.23e-06	7.78e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—APC—prostate cancer	7.18e-06	7.73e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CG—prostate cancer	7.18e-06	7.73e-05	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—IL2—prostate cancer	7.17e-06	7.72e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PDGFRB—prostate cancer	7.16e-06	7.71e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—CREBBP—prostate cancer	7.13e-06	7.68e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IRS1—prostate cancer	7.09e-06	7.64e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EGF—prostate cancer	7.09e-06	7.64e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CB—prostate cancer	7.09e-06	7.64e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—SLC22A1—prostate cancer	7.07e-06	7.62e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—SRC—prostate cancer	7.04e-06	7.58e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—GSK3B—prostate cancer	7.03e-06	7.57e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	6.99e-06	7.53e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ITGB3—prostate cancer	6.98e-06	7.52e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—INS—prostate cancer	6.94e-06	7.47e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—SULT2A1—prostate cancer	6.89e-06	7.42e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—GSK3B—prostate cancer	6.89e-06	7.42e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—VEGFA—prostate cancer	6.85e-06	7.38e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—CXCL8—prostate cancer	6.81e-06	7.34e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CREBBP—prostate cancer	6.79e-06	7.32e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—INS—prostate cancer	6.79e-06	7.31e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—STAT3—prostate cancer	6.79e-06	7.31e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—MED12—prostate cancer	6.78e-06	7.3e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ERBB3—prostate cancer	6.77e-06	7.29e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CD—prostate cancer	6.76e-06	7.28e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—FGFR2—prostate cancer	6.76e-06	7.28e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GNG5—prostate cancer	6.73e-06	7.25e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IGF1—prostate cancer	6.71e-06	7.23e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—EGFR—prostate cancer	6.68e-06	7.19e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CREBBP—prostate cancer	6.65e-06	7.16e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IGF1—prostate cancer	6.57e-06	7.08e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—EGFR—prostate cancer	6.54e-06	7.04e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL2—prostate cancer	6.51e-06	7.01e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TERT—prostate cancer	6.49e-06	6.99e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MAP2K1—prostate cancer	6.49e-06	6.98e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NCOA3—prostate cancer	6.48e-06	6.98e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CD—prostate cancer	6.44e-06	6.94e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—NOS3—prostate cancer	6.38e-06	6.87e-05	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—PIK3CA—prostate cancer	6.38e-06	6.87e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—SERPINE1—prostate cancer	6.37e-06	6.86e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.37e-06	6.86e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MAP2K1—prostate cancer	6.35e-06	6.84e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CD—prostate cancer	6.31e-06	6.79e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—KRAS—prostate cancer	6.31e-06	6.79e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—MYC—prostate cancer	6.31e-06	6.79e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TGFB1—prostate cancer	6.29e-06	6.77e-05	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—PIK3CA—prostate cancer	6.25e-06	6.73e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—SERPINE1—prostate cancer	6.24e-06	6.72e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HIF1A—prostate cancer	6.21e-06	6.68e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HPGDS—prostate cancer	6.18e-06	6.66e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—KRAS—prostate cancer	6.18e-06	6.65e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—FGF2—prostate cancer	6.17e-06	6.64e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—EGFR—prostate cancer	6.17e-06	6.64e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2C19—prostate cancer	6.14e-06	6.62e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—NOS3—prostate cancer	6.08e-06	6.55e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—LEP—prostate cancer	6.06e-06	6.52e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—FGF2—prostate cancer	6.04e-06	6.5e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CAV1—prostate cancer	6e-06	6.46e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTT1—prostate cancer	6e-06	6.46e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ACHE—prostate cancer	6e-06	6.46e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—NOS3—prostate cancer	5.96e-06	6.41e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KDR—prostate cancer	5.93e-06	6.39e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2A6—prostate cancer	5.93e-06	6.38e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—JAK2—prostate cancer	5.91e-06	6.37e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.91e-06	6.36e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CB—prostate cancer	5.89e-06	6.35e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PTGS2—prostate cancer	5.84e-06	6.29e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—KRAS—prostate cancer	5.83e-06	6.27e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—PIK3CA—prostate cancer	5.8e-06	6.24e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—JAK2—prostate cancer	5.79e-06	6.23e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ESR1—prostate cancer	5.78e-06	6.23e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MDM2—prostate cancer	5.77e-06	6.22e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—AKR1C3—prostate cancer	5.77e-06	6.21e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PRKACB—prostate cancer	5.74e-06	6.18e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—ERBB2—prostate cancer	5.69e-06	6.13e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP17A1—prostate cancer	5.68e-06	6.11e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—PIK3CA—prostate cancer	5.67e-06	6.11e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MDM2—prostate cancer	5.65e-06	6.09e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—BAD—prostate cancer	5.64e-06	6.08e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CB—prostate cancer	5.62e-06	6.05e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.6e-06	6.03e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—ERBB2—prostate cancer	5.57e-06	6e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CB—prostate cancer	5.5e-06	5.92e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CG—prostate cancer	5.47e-06	5.89e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—APC—prostate cancer	5.47e-06	5.89e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NCOA2—prostate cancer	5.41e-06	5.83e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IRS1—prostate cancer	5.4e-06	5.82e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EGF—prostate cancer	5.4e-06	5.82e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CXCL8—prostate cancer	5.4e-06	5.81e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—PIK3CA—prostate cancer	5.35e-06	5.76e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CXCL8—prostate cancer	5.28e-06	5.69e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CDKN1B—prostate cancer	5.27e-06	5.67e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—GSK3B—prostate cancer	5.25e-06	5.65e-05	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—AKT1—prostate cancer	5.21e-06	5.61e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—TP53—prostate cancer	5.18e-06	5.58e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—INS—prostate cancer	5.17e-06	5.57e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CASP3—prostate cancer	5.17e-06	5.56e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—SLC5A5—prostate cancer	5.16e-06	5.56e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	5.16e-06	5.56e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL2—prostate cancer	5.16e-06	5.55e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—IL6—prostate cancer	5.13e-06	5.53e-05	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	5.1e-06	5.5e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PTEN—prostate cancer	5.09e-06	5.48e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CREBBP—prostate cancer	5.07e-06	5.46e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CASP3—prostate cancer	5.06e-06	5.45e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL2—prostate cancer	5.05e-06	5.44e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP2E1—prostate cancer	5.04e-06	5.43e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CCND1—prostate cancer	5.03e-06	5.41e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—IL6—prostate cancer	5.02e-06	5.41e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IGF1—prostate cancer	5.01e-06	5.39e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NQO1—prostate cancer	4.98e-06	5.37e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—EGFR—prostate cancer	4.98e-06	5.36e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	4.98e-06	5.36e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CCND1—prostate cancer	4.92e-06	5.3e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TH—prostate cancer	4.91e-06	5.29e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MMP9—prostate cancer	4.88e-06	5.26e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.88e-06	5.26e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	4.88e-06	5.25e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	4.86e-06	5.24e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP3A4—prostate cancer	4.86e-06	5.23e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—EP300—prostate cancer	4.86e-06	5.23e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PTEN—prostate cancer	4.85e-06	5.23e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	4.84e-06	5.21e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.84e-06	5.21e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	4.81e-06	5.17e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MMP9—prostate cancer	4.78e-06	5.15e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP1B1—prostate cancer	4.78e-06	5.15e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	4.76e-06	5.13e-05	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	4.76e-06	5.13e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	4.75e-06	5.12e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PTEN—prostate cancer	4.75e-06	5.12e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—IL6—prostate cancer	4.74e-06	5.1e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—AKT1—prostate cancer	4.73e-06	5.1e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—KRAS—prostate cancer	4.7e-06	5.07e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—AKT1—prostate cancer	4.64e-06	4.99e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GGT1—prostate cancer	4.63e-06	4.98e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EP300—prostate cancer	4.63e-06	4.98e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—FGF2—prostate cancer	4.6e-06	4.95e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NCOA1—prostate cancer	4.56e-06	4.91e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—NOS3—prostate cancer	4.54e-06	4.89e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EP300—prostate cancer	4.53e-06	4.88e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—SRC—prostate cancer	4.5e-06	4.85e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP19A1—prostate cancer	4.49e-06	4.84e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—JAK2—prostate cancer	4.41e-06	4.75e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—SRC—prostate cancer	4.41e-06	4.74e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—VEGFA—prostate cancer	4.38e-06	4.72e-05	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—AKT1—prostate cancer	4.37e-06	4.71e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—STAT3—prostate cancer	4.34e-06	4.67e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—RXRA—prostate cancer	4.34e-06	4.67e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	4.32e-06	4.65e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MDM2—prostate cancer	4.31e-06	4.64e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—VEGFA—prostate cancer	4.29e-06	4.62e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—STAT3—prostate cancer	4.25e-06	4.58e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—ERBB2—prostate cancer	4.24e-06	4.57e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.22e-06	4.54e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	4.19e-06	4.51e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—COMT—prostate cancer	4.18e-06	4.5e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTP1—prostate cancer	4.16e-06	4.48e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ITPR1—prostate cancer	4.09e-06	4.4e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—MYC—prostate cancer	4.03e-06	4.34e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CXCL8—prostate cancer	4.03e-06	4.33e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TGFB1—prostate cancer	4.02e-06	4.33e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.02e-06	4.33e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—MYC—prostate cancer	3.95e-06	4.25e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—EGFR—prostate cancer	3.94e-06	4.25e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TGFB1—prostate cancer	3.94e-06	4.24e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	3.93e-06	4.23e-05	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	3.89e-06	4.19e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—TYMS—prostate cancer	3.86e-06	4.16e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—EGFR—prostate cancer	3.86e-06	4.16e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CASP3—prostate cancer	3.85e-06	4.15e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL2—prostate cancer	3.85e-06	4.14e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—IL6—prostate cancer	3.83e-06	4.12e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—GSTM1—prostate cancer	3.82e-06	4.11e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CCND1—prostate cancer	3.75e-06	4.04e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—LPL—prostate cancer	3.75e-06	4.04e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—KRAS—prostate cancer	3.73e-06	4.01e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	3.71e-06	4e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—KRAS—prostate cancer	3.65e-06	3.93e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MMP9—prostate cancer	3.64e-06	3.92e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	3.63e-06	3.91e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CYP1A1—prostate cancer	3.62e-06	3.9e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PTEN—prostate cancer	3.62e-06	3.9e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—PIK3CA—prostate cancer	3.59e-06	3.87e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—ERCC2—prostate cancer	3.59e-06	3.87e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—AKT1—prostate cancer	3.53e-06	3.8e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EP300—prostate cancer	3.45e-06	3.72e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	3.42e-06	3.69e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—MTHFR—prostate cancer	3.38e-06	3.64e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—SRC—prostate cancer	3.36e-06	3.61e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	3.35e-06	3.61e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PPARA—prostate cancer	3.31e-06	3.57e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—TP53—prostate cancer	3.31e-06	3.57e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—VEGFA—prostate cancer	3.27e-06	3.52e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—TP53—prostate cancer	3.24e-06	3.49e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—STAT3—prostate cancer	3.24e-06	3.49e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CAV1—prostate cancer	3.11e-06	3.35e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—IL6—prostate cancer	3.03e-06	3.26e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—MYC—prostate cancer	3.01e-06	3.24e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TGFB1—prostate cancer	3e-06	3.23e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.98e-06	3.2e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—IL6—prostate cancer	2.97e-06	3.2e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—EGFR—prostate cancer	2.94e-06	3.17e-05	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—AKT1—prostate cancer	2.93e-06	3.16e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.84e-06	3.05e-05	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—AKT1—prostate cancer	2.8e-06	3.01e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—KRAS—prostate cancer	2.78e-06	2.99e-05	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—AKT1—prostate cancer	2.74e-06	2.95e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—INS—prostate cancer	2.69e-06	2.89e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—CREBBP—prostate cancer	2.63e-06	2.83e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	2.55e-06	2.75e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CD—prostate cancer	2.49e-06	2.69e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—TP53—prostate cancer	2.47e-06	2.66e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—NOS3—prostate cancer	2.35e-06	2.54e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—IL6—prostate cancer	2.26e-06	2.43e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CB—prostate cancer	2.17e-06	2.34e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PTGS2—prostate cancer	2.15e-06	2.32e-05	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—AKT1—prostate cancer	2.09e-06	2.25e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PTEN—prostate cancer	1.88e-06	2.02e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—EP300—prostate cancer	1.79e-06	1.93e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.32e-06	1.43e-05	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—AKT1—prostate cancer	1.08e-06	1.17e-05	CbGpPWpGaD
